Table 1.

Summary of articles identified utilizing the reserpine model. Articles are grouped by their investigation of affect and cognition, as well as by treatments investigated for the alleviation of affective and cognitive deficits.

	Affective	Cognitive	Treatment for Affect/Cognition
Reserpine
Significant:	[22,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,72,73,74,75,76,77,78,79,80,81,82]	[68,69,70,76,83]	Antidepressants: [37,42,43,47,49,54,56,59,61,62,66,78,80,81] Parkinson’s DA agonist: [64,78] Anticonvulsants: [55,58,61,68,69,70,72,76,81] Neurorecovery/neuroprotective: [47,50,62] Organics: [38,44,49,52,58,60,61,63,66,68,69,70,74,75,76] Environment/Diet/Exercise: [53,56,72,83] Alternative Measures: [22,41,42,84] Other: [43,45,47,54,55,57,59,61]
Non-significant:	[83,85]	-	Anticonvulsants: [39,45,52,57,63,65] NSAID: [39,63,81] Opioid Partial Agonist: [81] Organics: [39,46,52] Alternative Measures: [22] Other: [22,43,51,57,85]
Inconclusive:	[80,86,87,88]	[80,88]	Benzodiazepines: [88] Organics: [86,87] Other: [88]
			Not Investigated: Antidepressants: [40] Anticonvulsants: [59] Other: [57,61,85,88]